ImmuPharma plc (LON:IMM – Get Free Report) traded up 168.7% during mid-day trading on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.22 ($0.04). 61,345,711 shares were traded during mid-day trading, an increase of 451% from the average session volume of 11,133,673 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Up 175.0 %
The stock has a market cap of £13.74 million, a P/E ratio of -330.00 and a beta of 1.53. The company’s 50 day moving average price is GBX 1.36 and its 200-day moving average price is GBX 1.63.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More
- Five stocks we like better than ImmuPharma
- Technology Stocks Explained: Here’s What to Know About Tech
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
- Insider Trading – What You Need to Know
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- Are Penny Stocks a Good Fit for Your Portfolio?
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
